Effects of aliskiren on blood pressure, albuminuria, and (Pro)renin receptor expression in diabetic TG(mRen-2)27 Rats

Hypertension

Volumn 52, Issue 1, 2008, Pages 130-136

  Feldman, David L ^a   Jin, Liang ^a   Xuan, Hong ^a   Contrepas, Aurelie ^b,c   Zhou, Yinong ^a   Webb, Randy L ^a   Mueller, Dominik N ^d   Feldt, Sandra ^d   Cumin, Frederick ^a   Maniara, Wieslawa ^a   Persohn, Elke ^e   Schuetz, Helmut ^e   Danser, A H Jan ^f   Nguyen, Genevieve ^b,c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b INSERM   (France)

^c l'alimentation et l'Environnement   (France)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

(pro)renin receptor; Aliskiren; Diabetic nephropathy; Renin inhibitor; TG(mRen 2)rat

Indexed keywords

ALISKIREN; COLLAGEN TYPE 1; MITOGEN ACTIVATED PROTEIN KINASE; PRORENIN; RENIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; AMIDE; ANTIHYPERTENSIVE AGENT; CELL SURFACE RECEPTOR; COLLAGEN TYPE 3; COLLAGEN TYPE 4; FUMARIC ACID DERIVATIVE; PRORENIN RECEPTOR;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; GENE EXPRESSION; GLOMERULUS; HISTOPATHOLOGY; IC 50; IN SITU HYBRIDIZATION; IN VITRO STUDY; KIDNEY TUBULE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; RENAL PROTECTION; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; ANIMAL; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY;

ALBUMINURIA; AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COLLAGEN TYPE I; COLLAGEN TYPE III; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FUMARATES; GENE EXPRESSION; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; RENIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 46449118638     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.108845     Document Type: Article

References (29)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angioten-sin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England J Med. 2001;345:861-869.
3. Gradman A, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.
4. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137-1143.
5. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Danser AHJ, Luft FC, Müller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46:569-576.
6. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427.
7. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasmin-ogen activator inhibitor-1 antigen. Kid Int. 1996;50:1897-1903.
8. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, an-giotensin II-independent mechanisms. Kid Int. 2006;69:105-113.
9. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest. 1996;98:1966-1970.
10. Prescott G, Silversides DW, Reudelhuber TL. Tissue activity of circulating prorenin. Am J Hypertens. 2002;15:280-285.
11. Nabi AH, Kageshima A, Uddin MN, Nakagawa T, Park EY, Suzuki F. Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. Int J Molec Med. 2006;18:483-488.
12. Derkx FH, Deinum J, Lipovski M, Verhaar M, Fischli W, Schalekamp MA. Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. J Biol Chem. 1992;267:22837-22842.
13. Menard J, Guyene TT, Peyrard S, Azziz M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens. 2006; 24:529-534.
14. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114:1128-1135.
15. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2006; 17:1950-1961.
16. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 1990;344:541-544.
17. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kid Int. 1998;154:343-352.
18. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. In press.
19. Suzuki F, Nakamura Y, Nagata Y, Ohsawa T, Murakami K. A rapid and large-scale isolation of renin from mouse submaxillary gland by pepstatin-aminohexyl-agarose affinity chromatography. J Biochem. 1981; 89:1107-1112.
20. Webb RL, Navarrete AE, Davis S. Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR). Am J Hypertens. 1998;11:59-65.
21. Burckle CA, Danser AHJ, Muller DN, Garrelds IM, Gasc JM, Popova E, Plehm R, Peters J, Bader M, Nguyen G. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension. 2006;47: 552-556.
22. Springate JE, Feld LG, Ganten D. Renal function in hypertensive rats transgenic for mouse renin gene. Am J Physiol. 1993;266:F731-F737.
23. Veniant M, Whitworth CE, Menard J, Sharp MG, Gonzales MF, Bruneval P, Mullins JJ. Developmental studies demonstrate age-dependent elevation of renin activity in TGR(mRen2)27 rats. Am J Hypertens. 1995; 8:1167-1176.
24. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol. In press.
25. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kid Int. 2004;65:2309-2320.
26. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 1998;31:181-188.
27. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi PP, Ruiz P, Unger T, Funke-Kaiser H. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res. 2006; 99:1355-1366.
28. Nguyen G. Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: put the blame on the (pro)renin receptor? Kid Int. 2006;70:618-620.
29. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 2007;72:45-52.